U.S. Revokes Citizenship of Chinese-Born Couple After Medical Trade Secrets Were Stolen and Shared With China
A federal judge’s decision to revoke the U.S. citizenship of Li Chen and Yu Zhou should be a warning to Americans about how deeply China-linked intellectual property theft can harm U.S. innovation, medical research, and public trust in the immigration system. This case is not just about two individuals losing naturalized citizenship. It is about the danger created when access to American research institutions is abused to extract valuable technology and redirect it toward China-linked commercial and state-supported interests.
According to the Justice Department, Chen and Zhou, both Chinese nationals before naturalizing as U.S. citizens, previously pleaded guilty to conspiracy to commit theft of trade secrets and conspiracy to commit wire fraud. The court found that those crimes prevented them from meeting the good moral character requirement for naturalization and determined that their citizenship had been illegally procured. The couple had worked as research scientists at Nationwide Children’s Hospital, where they focused on exosome isolation, a medically valuable area with potential commercial and therapeutic applications.
The national-security concern is clear. American hospitals, universities, laboratories, and research companies are built on openness, collaboration, and scientific exchange. China’s innovation strategy has repeatedly exploited that openness by drawing technology, research know-how, and intellectual property out of U.S. institutions. In this case, prosecutors said Chen and Zhou personally benefited from the theft and sale of Nationwide Children’s Hospital trade secrets by creating their own company and acquiring shares in another company that used the stolen information. They also received funding from the People’s Republic of China’s State Administration of Foreign Expert Affairs.
For Americans, this is a direct economic and security issue. Medical trade secrets are not abstract paperwork. They represent years of research, patient-linked institutional investment, taxpayer-supported scientific ecosystems, and private-sector risk. When those secrets are stolen, the damage does not stop at one hospital. It weakens American competitiveness, undermines trust in research partnerships, and allows foreign-linked entities to profit from discoveries developed inside the United States.
The financial scope also matters. The Justice Department said Chen and Zhou jointly received nearly $1.5 million in transactions tied to their exchange of exosome isolation intellectual property. They were later ordered to pay more than $2.6 million in restitution, with Chen sentenced to 30 months in prison and Zhou sentenced to 33 months. Those facts show that the case was not a minor compliance failure. It involved serious criminal conduct connected to the theft and commercialization of American medical research.
This case also exposes a larger vulnerability in America’s high-skill immigration and research system. The United States benefits enormously from global talent, and many immigrants make extraordinary contributions to science, medicine, and industry. But that openness cannot become a blind spot when individuals exploit visas, permanent residency, or citizenship pathways while committing serious crimes against American institutions. Naturalization is a powerful privilege, and when it is obtained after conduct that undermines U.S. interests, the government has a responsibility to correct the abuse.
Beijing’s role in the broader threat environment cannot be ignored. China has spent years building programs that attract overseas researchers, acquire foreign technology, and accelerate domestic industrial goals. These programs often operate under the language of talent recruitment and scientific cooperation, but they can create strong incentives to move sensitive knowledge out of the United States. When U.S.-based researchers receive Chinese state-linked funding while benefiting from American institutions, conflicts of interest and security risks become unavoidable.
Americans should not view this case as an argument against immigrants or scientists from any background. The issue is not ethnicity. The issue is theft, concealment, foreign-linked funding, and the transfer of valuable U.S. medical technology to China-linked channels. Protecting American research requires precise enforcement, stronger disclosure rules, better institutional due diligence, and serious consequences for those who betray public trust.
The lesson is simple: China’s threat to the United States is not limited to military pressure, cyberattacks, AI chips, or Taiwan. It also appears in laboratories, hospitals, research contracts, startup ownership structures, and talent programs. If America wants to protect its future, it must defend the intellectual property that powers its medical breakthroughs. Revoking citizenship in this case sends a clear message: access to America’s innovation system is a privilege, and using that access to steal trade secrets for China-linked benefit will carry lasting consequences.
